

# company announcement

## Novo Nordisk – major shareholder announcement

**Bagsværd, Denmark, 7 June 2022** – Novo Nordisk today announced that the company has been notified by BlackRock, Inc. (Blackrock) that Blackrock as of 31 May 2022 holds B shares equal to below 5% of the entire share capital of Novo Nordisk. The announcement is in accordance with section 30 of the Danish Capital Markets Act.

The total B shares according to section 38 of the Danish Capital Markets Act, and other financial instruments according to section 39(2)(1) of the Danish Capital Markets Act and financial instruments with similar effects according to section 39(2)(2) of the Danish Capital Markets Act held by Blackrock correspond to below 5% of the entire share capital and below 5% of the voting rights.

For a full chain of controlled undertakings through which the voting rights and/or the financial instruments are held, please see the annex.

### About Novo Nordisk

*Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). or more information, visit [novonordisk.com](https://www.novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#) and [YouTube](#).*

## Further information

### Media:

Ambre Brown Morley	+45 3079 9289	<a href="mailto:abmo@novonordisk.com">abmo@novonordisk.com</a>
Natalia Salomao Abrahao	+1 848 304 1027	<a href="mailto:niaa@novonordisk.com">niaa@novonordisk.com</a>

### Investors:

Daniel Muusmann Bohsen	+45 3075 2175	<a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a>
Ann Søndermølle Rendbæk	+45 3075 2253	<a href="mailto:arnd@novonordisk.com">arnd@novonordisk.com</a>
David Heiberg Landsted	+45 3077 6915	<a href="mailto:dhel@novonordisk.com">dhel@novonordisk.com</a>
Jacob Martin Wiborg Rode	+45 3075 5956	<a href="mailto:jrde@novonordisk.com">jrde@novonordisk.com</a>
Mark Joseph Root (US)	+1 848 213 3219	<a href="mailto:mjhr@novonordisk.com">mjhr@novonordisk.com</a>

**Annex: Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity as of 31 May 2022**

Name	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold
BlackRock Japan Co., Ltd.			Below 5%
BlackRock Investment Management, LLC			Below 5%
BlackRock Investment Management (UK) Limited			Below 5%
BlackRock Investment Management (Australia) Limited			Below 5%
BlackRock International Limited			Below 5%
BlackRock Institutional Trust Company, National Association			Below 5%
BlackRock Fund Advisors			Below 5%
BlackRock Financial Management, Inc.			Below 5%
BlackRock Asset Management North Asia Limited			Below 5%
BlackRock Asset Management Deutschland AG			Below 5%
BlackRock Asset Management Canada Limited			Below 5%
BlackRock Advisors, LLC			Below 5%
BlackRock Advisors (UK) Limited			Below 5%
BlackRock (Singapore) Limited			Below 5%

BlackRock Asset Management Ireland Limited			Below 5%
Aperio Holdings, LLC			Below 5%